Loading company details...
Beta
Latest Form 4 (Sep 17, 2026): David E. I. Pyott (Director): Exercise/Conversion of 201 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 17, 2026 | David E. I. Pyott | Exercise/Conversion | 201 | n/a |
| Sep 17, 2026 | Wendy L. Yarno | Exercise/Conversion | 302 | n/a |
| Sep 17, 2026 | William J. Link Phd. | Exercise/Conversion | 201 | n/a |
| Sep 9, 2026 | Bobak R. Azamian, President/CEO and Board Chair | Sale | 7,100 | $640.9K |
| Sep 9, 2026 | Elizabeth Yeu Lin, Chief Medical Officer | Sale | 5,387 | $457.9K |
| Sep 9, 2026 | Seshadri Neervannan, Chief Operating Officer | Sale | 4,564 | $387.9K |
| Sep 3, 2026 | Bobak R. Azamian, President/CEO and Board Chair | Sale | 10,000 | $800.6K |
| Sep 3, 2026 | Elizabeth Yeu Lin, Chief Medical Officer | Sale | 4,601 | $339.8K |
| Jun 29, 2026 | Katherine Goodrich | Grant/Award | 3,837 | n/a |
| Jun 29, 2026 | Andrew D. Goldberg | Grant/Award | 3,837 | n/a |